Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pheochromocytoma: early-phase trial registry
8 of 15 indexed Pheochromocytoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Pheochromocytoma: 15 US clinical trials tracked, 8 recruiting.
Pheochromocytoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition pheochromocytoma
OPEN 8 | RECR 53% | LATE 0 | EARLY 12 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
Pheochromocytoma lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pheochromocytoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pheochromocytoma is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pheochromocytoma research.
National Cancer Institute (NCI) accounts for 4 of 15 trials (26.7%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Pheochromocytoma enrolment sits around 66 participants.
Median target enrolment is 66 among the 15 trials that report a genuine target (sentinel values excluded). 8 of those (53.3%) plan for fewer than 100 participants.
-
Pheochromocytoma research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Diagnosis of Pheochromocytoma
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00004847
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
NCT03160274
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
University of Pennsylvania
NCT06377033
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
NCT05636618
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
NCT00107289
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
NCT03206060
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Cancer Institute (NCI)
NCT06427798
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Heather Wachtel
NCT05636540
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
NCT03541720
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Advanced Accelerator Applications
NCT04711135
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Antonio Fojo
NCT03946527
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
NCT03839498
Blood Sampling for Neurochemical and Genetic Testing
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001147
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Cancer Institute (NCI)
NCT00923481
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Cancer Institute (NCI)
NCT01967576
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Pheochromocytoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pheochromocytoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pheochromocytoma page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Pheochromocytoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Pheochromocytoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pheochromocytoma condition card totals 15 registered trials; most-linked intervention Fostamatinib disodium; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.